Clinical Trial
Published on 29 Jul 2024
Efficacy and safety of a proposed omalizumab biosimilar compared to the reference product in the management of uncontrolled moderate-to-severe allergic asthma: a multicenter, phase III, randomized, double-blind, equivalency clinical trial
in Vaccines and Molecular Therapeutics
- 439 views